supra-luminous LED
Device810 nm light-emitting diode for the delivery of 2.1 J/cm2 to the brain.
Other names: unilateral trancranial photobiomodulation, near-infrared mode
NCT Number: NCT04340622
Investigators will test, for safety and efficacy, a novel treatment for opiate addiction that applies a 4-minute treatment of intense near infra-red light to stimulate a side of the brain that the investigators determine to be healthier, more mature, and less traumatized. Investigators will compare an active and a sham treatment given twice weekly for 4-weeks. Investigators hope this will lead to a significant weapon in the battle against the opioid epidemic as well as lead to psychological and physiological insights into possible relations among trauma, cerebral laterality, and addiction.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
McLean Hospital, Belmont, Massachusetts, United States
This project is to demonstrate that a novel treatment for opiate addiction is safe and far superior to a sham comparison treatment. The treatment is hoped to significantly aid in the battle against the opioid epidemic that is ravaging much of the country and the world. The treatment consists of using a 4-minute application of transcranial photobiomodulation, near infra-red mode, through a supra-luminous LED, to one side of the forehead over the brain hemisphere that we determine (through a proprietary test) to have a more positive emotional valence. Based on preliminary data, we anticipate that the treatment will be very effective in reducing drug cravings, anxiety, and depression as well as in reducing relapses. Aim I will offer twice-weekly treatments to two groups, active and sham, for 4-weeks and will look specifically for differences in opioid cravings, anxiety, depression, and opioid use. The investigators will evaluate participants weekly for safety and efficacy for 3-weeks post-treatment. In Aim II a highly-regarded product engineer will work with the company to design a marketable product that may have patentable elements.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
810 nm light-emitting diode for the delivery of 2.1 J/cm2 to the brain.
Other names: unilateral trancranial photobiomodulation, near-infrared mode
Light-emitting diode covered with aluminium foil
Time frame: One year
a published 3 question scale of opioid cravings. Each question asks the patient to rate his opioid cravings at the present time from 0 (none) to 9 (extreme). We use the average of the scores of the 3 questions. A low score is best.
Time frame: One year
TimeLine FollowBack method, measures the daily amount of opioid drug use (mg's of pills or grams used) for the period between observations.
Time frame: One year
patient reports supported by urine drug screens and a drug hair test at the end of the study
MindLight, LLC
Industry
A Project to Test The Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03773523
Chemically-Induced Disorders, Mental Disorders
Minneapolis, Minnesota, United States
View Trial DetailsNCT04464421
Behavior, Chemically-Induced Disorders
Memphis, Tennessee, United States
View Trial DetailsNCT04601480
Chemically-Induced Disorders, Mental Disorders
Minneapolis, Minnesota, United States
View Trial DetailsNCT04601493
Chemically-Induced Disorders, Mental Disorders
Minneapolis, Minnesota, United States
View Trial Details